Ceredex Value Advisors LLC acquired a new stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,063,257 shares of the medical technology company’s stock, valued at approximately $92,503,000. Hill-Rom accounts for 1.1% of Ceredex Value Advisors LLC’s investment portfolio, making the stock its 17th largest position.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in shares of Hill-Rom by 57.5% during the first quarter. ClariVest Asset Management LLC now owns 58,523 shares of the medical technology company’s stock valued at $5,093,000 after purchasing an additional 21,360 shares during the period. Stevens Capital Management LP bought a new stake in shares of Hill-Rom during the first quarter valued at approximately $1,938,000. Thrivent Financial for Lutherans increased its position in shares of Hill-Rom by 1,443.9% during the first quarter. Thrivent Financial for Lutherans now owns 220,799 shares of the medical technology company’s stock valued at $19,209,000 after purchasing an additional 206,498 shares during the period. Aperio Group LLC increased its position in shares of Hill-Rom by 5.9% during the first quarter. Aperio Group LLC now owns 24,683 shares of the medical technology company’s stock valued at $2,147,000 after purchasing an additional 1,372 shares during the period. Finally, Front Barnett Associates LLC acquired a new stake in Hill-Rom in the 1st quarter valued at $1,770,000. Institutional investors and hedge funds own 84.49% of the company’s stock.
Shares of HRC stock opened at $89.78 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 1.34. The firm has a market capitalization of $5.81 billion, a P/E ratio of 23.26, a P/E/G ratio of 1.34 and a beta of 0.98. Hill-Rom Holdings, Inc. has a one year low of $87.60 and a one year high of $89.61.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, April 27th. The medical technology company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.03. The company had revenue of $710.50 million for the quarter, compared to analyst estimates of $707.54 million. Hill-Rom had a return on equity of 20.18% and a net margin of 6.85%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.88 earnings per share. research analysts expect that Hill-Rom Holdings, Inc. will post 4.62 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 22nd will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Thursday, June 21st. Hill-Rom’s dividend payout ratio is currently 20.73%.
Several analysts recently commented on the company. Zacks Investment Research raised Hill-Rom from a “hold” rating to a “buy” rating and set a $99.00 price target on the stock in a research note on Thursday, January 18th. KeyCorp reaffirmed a “buy” rating and issued a $97.00 price target on shares of Hill-Rom in a research note on Thursday, January 18th. Needham & Company LLC reaffirmed a “buy” rating on shares of Hill-Rom in a research note on Friday, January 26th. Goldman Sachs assumed coverage on Hill-Rom in a research note on Wednesday, April 4th. They issued a “neutral” rating and a $85.00 price target on the stock. Finally, ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a research note on Friday, March 2nd. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $94.00.
In other Hill-Rom news, SVP Deborah Rasin sold 7,590 shares of the business’s stock in a transaction on Thursday, April 12th. The stock was sold at an average price of $86.02, for a total value of $652,891.80. Following the transaction, the senior vice president now owns 14,028 shares of the company’s stock, valued at $1,206,688.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.90% of the stock is currently owned by insiders.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.